Common Stock, Value, Issued of Rubius Therapeutics, Inc. from 31 Dec 2017 to 31 Dec 2022
- Taxonomy & unit
- us-gaap: USD
- Description
- Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
- Summary
-
Rubius Therapeutics, Inc. quarterly Common Stock, Value, Issued in USD history and change rate from 31 Dec 2017 to 31 Dec 2022.
- Rubius Therapeutics, Inc. Common Stock, Value, Issued for the quarter ending 31 Dec 2022 was $90,000, unchanged year-over-year.
- Source SEC data
- View on sec.gov
Common Stock, Value, Issued, Quarterly (USD)
Common Stock, Value, Issued, YoY Quarterly Change (%)
Rubius Therapeutics, Inc. Quarterly Common Stock, Value, Issued (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2022 | $90,000 | $0 | 0% | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2022 | $90,000 | $0 | 0% | 30 Sep 2022 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $90,000 | $0 | 0% | 30 Jun 2022 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $90,000 | +$1,000 | +1.1% | 31 Mar 2022 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2021 | $90,000 | +$9,000 | +11% | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2021 | $90,000 | +$9,000 | +11% | 30 Sep 2021 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2021 | $90,000 | +$10,000 | +12% | 30 Jun 2021 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2021 | $89,000 | +$9,000 | +11% | 31 Mar 2021 | 10-Q/A | 20 Aug 2021 | 2021 | Q1 |
| Q4 2020 | $81,000 | +$1,000 | +1.2% | 31 Dec 2020 | 10-K | 25 Feb 2022 | 2021 | FY |
| Q3 2020 | $81,000 | +$1,000 | +1.2% | 30 Sep 2020 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2020 | $80,000 | $0 | 0% | 30 Jun 2020 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2020 | $80,000 | $0 | 0% | 31 Mar 2020 | 10-Q | 11 May 2020 | 2020 | Q1 |
| Q4 2019 | $80,000 | +$1,000 | +1.3% | 31 Dec 2019 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q3 2019 | $80,000 | +$1,000 | +1.3% | 30 Sep 2019 | 10-Q | 14 Nov 2019 | 2019 | Q3 |
| Q2 2019 | $80,000 | +$65,000 | +433% | 30 Jun 2019 | 10-Q | 13 Aug 2019 | 2019 | Q2 |
| Q1 2019 | $80,000 | 31 Mar 2019 | 10-Q | 15 May 2019 | 2019 | Q1 | ||
| Q4 2018 | $79,000 | +$64,000 | +427% | 31 Dec 2018 | 10-K | 12 Mar 2020 | 2019 | FY |
| Q3 2018 | $79,000 | 30 Sep 2018 | 10-Q | 13 Nov 2018 | 2018 | Q3 | ||
| Q2 2018 | $15,000 | 30 Jun 2018 | 10-Q | 31 Aug 2018 | 2018 | Q2 | ||
| Q4 2017 | $15,000 | 31 Dec 2017 | 10-K | 28 Mar 2019 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.